Gagner J.P. et al. demonstrated that the combination of POL5551 and B20-4.1.1, an anti-VEGF antibody, reduced tumor invasiveness, vascular density, and reduced Iba1-positive microglia TAM population within tumors compared to antivascular therapy alone in preclinical GBM mouse models [65]. This evidence concerns the gene VEGFA and glioblastoma.